Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Expert Opinion on Drug Discovery|May 31, 2021
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancerFlorian Wittlinger, Stefan A LauferJournal of Medicinal Chemistry|April 4, 2020
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole InhibitorsDavid E Heppner, Marcel Günther, Florian Wittlinger, et al.Methods in Enzymology|May 28, 2023
Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitorsTahereh Damghani, Florian Wittlinger, Tyler S Beyett, et al.Archiv Der Pharmazie|July 16, 2025
Structure-Activity Relationships of Inactive-Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric PocketsSurbhi P Chitnis, Florian Wittlinger, Mareike Möllers, et al.Journal of Medicinal Chemistry|December 22, 2023
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor InhibitorsKristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, et al.Journal of Medicinal Chemistry|April 11, 2024
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr ElectrophilesMoritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.ACS Medicinal Chemistry Letters|December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.Research Square|October 4, 2023
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsDavid Heppner, Florian Wittlinger, Blessing Ogboo, et al.Journal of Medicinal Chemistry|October 20, 2021
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric SitesFlorian Wittlinger, David E Heppner, Ciric To, et al.Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.Pageof 2